Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2024-09-26 Regulatory Filings
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
Letter from former auditor.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from KPMG LLP addressed to various securities commissions and the TSX Venture Exchange, dated September 25, 2024. It references a "Notice of Change of Auditors" for LSL Pharma Group Inc. The letter states agreement with the Notice except for one paragraph, indicating it is a response or confirmation related to the auditor change notice. The document is short (1023 characters) and does not contain any financial statements or detailed audit report content. It is essentially a certification or attestation letter related to a regulatory notice. According to the rules, such officer certifications or confirmations should be classified as Regulatory Filings (RNS), not as Audit Reports (AR) or other report types. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-26 English
Notice.pdf
Audit Report / Information Classification · 95% confidence The document is a notice regarding a change of auditors for LSL Pharma Group Inc., addressed to regulatory bodies and the outgoing and incoming auditors. It references National Instrument 51-102, which governs continuous disclosure obligations including auditor changes. The document confirms the resignation of the predecessor auditor and appointment of the successor auditor, with no modified opinions or reportable events. The content is a formal announcement of auditor change rather than a full audit report or annual report. The document length is short (1764 characters), and it serves as a regulatory notification. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports and related auditor information excluding full annual reports.
2024-09-26 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of LSL Pharma Group's financial and operating results for the second quarter and year-to-date periods ended June 30, 2024. It includes comprehensive financial data such as revenues, operating profits, adjusted EBITDA, net loss, and comparisons to prior periods. It also discusses corporate highlights including financing activities, acquisition, and board changes. The presence of detailed financial results for a quarter and year-to-date period, along with management commentary, indicates this is a quarterly financial report. The document is about 11,697 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings by the CFO of LSL Pharma Group Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2024. The document is a certification letter, not the interim report itself, and it explicitly states it is a Venture Issuer Basic Certificate under Regulation 52-109. It does not contain actual financial data or substantive financial analysis but is an attestation of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report (IR). The document length is 7,084 characters, which is sufficient to contain the full certification text but not the full interim report. Therefore, the correct classification is Regulatory Filings (RNS) with high confidence.
2024-08-25 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings for a venture issuer, specifically certifying the interim financial report and interim MD&A for the period ended June 30, 2024. It is a certification letter by the CEO confirming the review and fair presentation of the interim filings. The document does not contain the actual interim financial statements or substantive financial data but is an officer certification related to interim filings. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 7077 characters, which is sufficient for a certification letter but does not include the full interim report. Therefore, the correct classification is Regulatory Filings (RNS) with high confidence.
2024-08-25 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled "Management’s Discussion and Analysis for the three and six-month periods ended June 30, 2024 and 2023" and contains detailed discussion of financial condition, operating results, non-IFRS measures, business strategy, acquisitions, and corporate developments. It references unaudited condensed interim consolidated financial statements for the quarter ended June 30, 2024, indicating it is a quarterly or interim report. The length is substantial (15,000 characters), and it contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.